Can Vitamin E and Selenium Prevent Alzheimer's Disease in Older Men
A large prevention trial tested whether vitamin E and selenium supplements could ward off Alzheimer's and dementia in men over 55.
Summary
PREADVISE was a large-scale clinical trial enrolling over 4,200 men to determine whether supplementation with vitamin E (alpha-tocopherol) and/or selenium could prevent the onset of Alzheimer's disease and memory loss. Conducted as a companion to the SELECT cancer prevention trial, participants were randomized to receive one or both supplements, or a placebo, and were followed for over a decade. Alzheimer's disease is among the most feared consequences of aging, and antioxidant strategies have long been hypothesized to protect the aging brain from oxidative damage. This trial offered one of the most rigorous, longest-running tests of that hypothesis in a general male population. Results from this completed trial contribute essential evidence on whether widely available over-the-counter supplements can meaningfully alter dementia risk.
Detailed Summary
Alzheimer's disease represents one of the most devastating age-related conditions, with no cure and limited treatment options. Identifying preventive interventions — particularly inexpensive, widely accessible ones like vitamins and minerals — has therefore been a major priority in longevity and brain-health research. PREADVISE was designed to address this directly.
The trial enrolled 4,246 men aged 55 and older, piggybacking on the infrastructure of the SELECT trial, which was already investigating vitamin E and selenium for prostate cancer prevention. Participants were randomized into four groups: vitamin E alone (400 IU alpha-tocopherol), selenium alone (200 mcg), both supplements combined, or placebo. The study ran from 2002 to 2016, providing an unusually long follow-up window for a supplement prevention trial.
The primary question was whether either supplement — or their combination — could reduce the incidence of Alzheimer's disease and cognitive decline. Both nutrients have theoretical mechanistic support: vitamin E is a fat-soluble antioxidant that may protect neural membranes from oxidative stress, while selenium supports antioxidant enzyme systems such as glutathione peroxidase. Both have shown neuroprotective signals in preclinical and observational research.
The implications of a positive finding would be enormous, offering a low-cost, globally scalable prevention strategy for one of aging's most feared diseases. However, prior trials of antioxidants have frequently disappointed when rigorously tested, and SELECT itself found that the combination of vitamin E and selenium may actually increase certain health risks.
Caveats are significant: this summary is based solely on the trial registration abstract, and full published results are needed to draw firm conclusions. The all-male enrollment limits generalizability to women. Additionally, SELECT was terminated early due to safety signals, which may have affected PREADVISE follow-up and statistical power.
Key Findings
- Trial tested whether vitamin E and/or selenium supplements could prevent Alzheimer's disease in men over 55.
- Over 4,200 participants enrolled, with follow-up spanning more than 14 years — unusually long for a supplement trial.
- Both nutrients have antioxidant mechanisms theorized to protect aging brain tissue from oxidative damage.
- Trial was linked to SELECT, which raised safety concerns about the vitamin E and selenium combination.
- Results from this completed trial are critical for guiding supplement recommendations in dementia prevention.
Methodology
PREADVISE was a randomized, placebo-controlled trial with a 2x2 factorial design, enrolling 4,246 men as an ancillary study to the SELECT trial. Participants received alpha-tocopherol (vitamin E), selenium, both supplements, or placebo, with follow-up from 2002 to 2016. Primary outcome was incidence of Alzheimer's disease and dementia-related memory loss.
Study Limitations
This summary is based on the trial registration abstract only; full published results were not available, so specific outcome data and statistical findings cannot be reported. The study enrolled only men, limiting applicability to women who face substantial Alzheimer's risk. SELECT's early termination for safety concerns may have reduced PREADVISE's statistical power and altered the enrolled population.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: